PERJETA (pertzumab) from Roche
Products has had its extension of
indication approved and detailed in
the latest AusPAR addition.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 25 Aug 16 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Aug 16
CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).